Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication

AIDS

Volumn 19, Issue 18, 2005, Pages 2087-2095

  Heredia, Alonso ^a   Davis, Charles ^a   Bamba, Douty ^a   Le, Nhut ^a   Gwarzo, Muhammad Y ^a   Sadowska, Mariola ^a   Gallo, Robert C ^a   Redfield, Robert R ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Drug resistance; P TEFb; Tat

Indexed keywords

CYCLIN DEPENDENT KINASE 9; FLAVOPIRIDOL; INDIRUBIN; INDIRUBIN 3' MONOXIME; INDOLE DERIVATIVE; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN SUBUNIT; RIBONUCLEASE; ROSCOVITINE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA; CYCLIN DEPENDENT KINASE; FLAVONOID; INDIRUBIN-3'-MONOXIME; OXIME; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CELL PROLIFERATION; CHINESE MEDICINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; LYMPHOCYTE; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSCRIPTION; CELL STRAIN U937; DRUG ANTAGONISM; DRUG SCREENING; METHODOLOGY; PHYSIOLOGY; VIROLOGY;

CYCLIN-DEPENDENT KINASES; DRUG EVALUATION; FLAVONOIDS; HIV-1; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; OXIMES; PIPERIDINES; POSITIVE TRANSCRIPTIONAL ELONGATION FACTOR B; PROTEIN KINASE INHIBITORS; PURINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; U937 CELLS; VIRUS REPLICATION;

EID: 27944474355     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000194805.74293.11     Document Type: Article

References (33)

1. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
2. Dayton AI, Sodroski JG, Rosen CA, Goh WC, Haseltine WA. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986; 44:941-947.
3. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, et al. The trans activator gene of HTLV-III is essential for virus replication. Nature 1986; 320:367-371.
4. Mancebo HSY, Lee G, Flygare J, Tomassini J, Lu P, Zhu Y, et al. P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. Genes Dev 1997; 11:2633-2644.
5. Zhu Y, Pe'ery T, Peng J, Ramanathan Y, Marshall N, Marshall T, et al. Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev 1997; 11:2622-2632.
6. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000; 20: 2629-2634.
7. Flores O, Lee G, Kessler J, Miller M, Schlief W, Tomassini J, et al. Host-cell positive transcription elongation factor b kinase activity is essential and limiting for HIV type 1 replication. Proc Natl Acad Sci USA 1999; 96:7208-7213.
8. Wei P, Garber ME, Fang S, Fischer WH, Jones KA. A novel CDK9-associated c-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92:451-462.
9. Chiu Y, Cao H, Jacque J, Stevenson M, Rana TM. Inhibition of Human Immunodeficiency Virus type 1 replication by RNA interference directed against human Transcription Elongation Factor P-TEFb (CDK9/Cyclin T1). J Virol 2004; 78:2517-2529.
10. Hoessel R, Leclerc S, Endicott JA, Nobel MEM, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biol 1999; 1:60-67.
11. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and Meisoindigo in the treatment of Chronic Myelogenous Leukemia in China. Lymphoma 2002; 43:1763-1768.
12. Li C, Go Y, Mao Z, Koyano K, Kai Y, Kanehisa N, et al. The Synthesis, antileukemic activity, and crystal structure of indirubin derivatives. Bull Chem Soc Jpn 1996; 69:1621-1627.
13. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 Is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002; 13:4622-4637.
14. Hermankova M, Siliciano J, Zhou D, Monie D, Chadwick K, Margolick J, et al. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 2003; 77:7383-7392.
15. Adams M, Sharmeen L, Kimpton J, Romeo JM, Garcia JV, Peterlin BM, et al. Cellular latency in Human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts. Proc Natl Acad Sci USA 1994; 91:3862-3866.
16. Chao S, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-28348.
17. Chao S, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in Vivo. J Biol Chem 2001; 276:31793-31799.
18. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol and Cell Bio 1997; 17:1817-1823.
19. Cujec PT, Okamoto H, Fujinaga K, Meyer J, Chamberlin H, Morgan DO, et al. The HIV transaction TAT binds to CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev 1997; 11:2645-2657.
20. Peng J, Zhu Y, Milton JT, Price DH. Identification of multiple cyclin subunits of human P-TEFb. Genes Dev 1998; 12:755-762.
21. Isel C, Karn J. Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphoshorylation during transcriptional elongation. J Mol Biol 1999; 290:929-941.
22. Emiliani S, Fischle W, Ott M, Lint CV, Amelia CA, Verdin E. Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol 1998; 72:1666-1670.
23. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells non-productively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency. Cell 1990; 61:1271-1276.
24. Michael NL, Morrow P, Mosca J, Vahey M, Burke D, Redfield RR. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in rna splicing patterns. J Virol 1991; 65:1291-1303.
25. Kao SY, Calman A, Luciw P, Peterlin BM. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature 1987; 330:489-493.
26. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 1993; 365:451-453.
27. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small molecule CCR5 inhibitor. J Virol 2004; 78:2790-2807.
28. Polychronopoulos P, Magiatis P, Skaltsounis A, Myrianthopoulos V, Mikros E, Tarricone A, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem 2004; 47:935-946.
29. Wang D, de la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001; 75:7266-7279.
30. Zhou M, Deng L, Lacoste V, Park H, Pumfery A, Kashanchi F, et al. Coordination of transcription factor phosphorylation and histone methylation by the P-TEFb kinase during human immunodeficiency virus type 1 transcription. J Virol 2004; 78:13522-13533.
31. Nelson P, D'Agati V, Gries J, Suarez J, Gelman I. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J Antimicrob Chemother 2003; 51:921-929.
32. Schang LM. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs. Curr Drug Targets Infect Disord 2005; 5:29-37.
33. Schang LM, Bantly A, Knockaert M, Shaheen F, Meijer L, Malim MH, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral proteins. J Virol 2002; 76:7874-7882.